Johnson & Johnson (NYSE: JNJ) has been a prominent player in the healthcare sector, with its stock currently trading around $160 per share, showing potential for growth. Despite facing challenges such as talc lawsuits and patent expirations, the company has managed to maintain its position in the market.
Over the past few years, JNJ stock has experienced fluctuations in performance compared to the broader S&P 500 index. While it underperformed in 2021 and 2023, there are indications that it could see a rise in the coming months.
